Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature
Abstract Introduction Decision-making regarding adjuvant chemotherapy has been based on clinical and pathological features. However, such decisions are seldom consistent. Web-based predictive models have been developed using data from cancer registries to help determine the need for adjuvant therapy...
Gespeichert in:
| Veröffentlicht in: | The American journal of surgery 2018-01, Vol.215 (1), p.171-178 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 178 |
|---|---|
| container_issue | 1 |
| container_start_page | 171 |
| container_title | The American journal of surgery |
| container_volume | 215 |
| creator | El HageChehade, Hiba Wazir, Umar Mokbel, Kinan Kasem, Abdul Mokbel, Kefah |
| description | Abstract Introduction Decision-making regarding adjuvant chemotherapy has been based on clinical and pathological features. However, such decisions are seldom consistent. Web-based predictive models have been developed using data from cancer registries to help determine the need for adjuvant therapy. More recently, with the recognition of the heterogenous nature of breast cancer, genomic assays have been developed to aid therapeutic decision-making. Methods We have carried out a comprehensive literature review regarding online prognostication tools and genomic assays to assess whether online tools could be used as valid alternatives to genomic profiling in decision-making regarding adjuvant therapy in early breast cancer. Results and conclusion s: Breast cancer has been recently recognized as a heterogenous disease based on variations in molecular characteristics. Online tools are valuable in guiding adjuvant treatment, especially in resource constrained countries. However, in the era of personalized therapy, molecular profiling appears to be superior in predicting clinical outcome and guiding therapy. |
| doi_str_mv | 10.1016/j.amjsurg.2017.05.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1910797214</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002961017305317</els_id><sourcerecordid>1977144310</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-5b71aa4bd70bc26f8c3094e9969106ff47a99da024457354098f80e457af3fb53</originalsourceid><addsrcrecordid>eNqFksFu1DAQhi0EotuFRwBZ4sIlwU6cOLlQVYUCUiUOwNlynMni4MSL7Szsg_F-TLQLSL1wsWXrn280_z-EPOMs54zXr8ZcT2Ncwi4vGJc5q3LG6gdkwxvZZrxpyodkwxgrsrbm7IJcxjjik3NRPiYXRVMXRSP4hvx646mfnZ2B7oPfzT4ma3SyfqbJexdpgH2ACHOimh60sz3VLkGYUXMA1NAdzH6yZi0fLIJ21GLtV6DGzwl-JuoHqvtxOWhkpAA6TSsNf0EHd6QdfsVEjZ4NhCt6TeMxJpiQb7D5wcKPVbsCncXGOi0BnpBHg3YRnp7vLfly-_bzzfvs7uO7DzfXd5kRoklZ1Umuteh6yTpT1ENjStYKaNu65aweBiF12_aaFUJUsqwEa5uhYYAPPZRDV5Vb8vLExeG-LxCTmmw04JyewS9RceTIVhbo6pa8uCcd_YI2uVUlJRei5AxV1Ullgo8xwKD2wU46HBVnas1Vjeqcq1pzVaxSmCvWPT_Tl26C_m_VnyBRcHUSANqBpgUVjQW0tLcBTFK9t_9t8foewWCauAzuGxwh_ptGxUIx9WldrnW3uCxZVeL5G1jizw8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1977144310</pqid></control><display><type>article</type><title>Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature</title><source>Elsevier ScienceDirect Journals Complete</source><creator>El HageChehade, Hiba ; Wazir, Umar ; Mokbel, Kinan ; Kasem, Abdul ; Mokbel, Kefah</creator><creatorcontrib>El HageChehade, Hiba ; Wazir, Umar ; Mokbel, Kinan ; Kasem, Abdul ; Mokbel, Kefah</creatorcontrib><description>Abstract Introduction Decision-making regarding adjuvant chemotherapy has been based on clinical and pathological features. However, such decisions are seldom consistent. Web-based predictive models have been developed using data from cancer registries to help determine the need for adjuvant therapy. More recently, with the recognition of the heterogenous nature of breast cancer, genomic assays have been developed to aid therapeutic decision-making. Methods We have carried out a comprehensive literature review regarding online prognostication tools and genomic assays to assess whether online tools could be used as valid alternatives to genomic profiling in decision-making regarding adjuvant therapy in early breast cancer. Results and conclusion s: Breast cancer has been recently recognized as a heterogenous disease based on variations in molecular characteristics. Online tools are valuable in guiding adjuvant treatment, especially in resource constrained countries. However, in the era of personalized therapy, molecular profiling appears to be superior in predicting clinical outcome and guiding therapy.</description><identifier>ISSN: 0002-9610</identifier><identifier>EISSN: 1879-1883</identifier><identifier>DOI: 10.1016/j.amjsurg.2017.05.006</identifier><identifier>PMID: 28622841</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adjuvant ; Adjuvant therapy ; Breast cancer ; Cancer ; Cancer therapies ; Chemotherapy ; Cost analysis ; Decision making ; Gene expression ; Genetic testing ; Genomes ; Genomics ; Internet ; Literature reviews ; Medical prognosis ; Patients ; Prediction models ; Prognosis ; Studies ; Surgery ; Systematic review</subject><ispartof>The American journal of surgery, 2018-01, Vol.215 (1), p.171-178</ispartof><rights>2017 Elsevier Inc.</rights><rights>Copyright © 2017 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Jan 1, 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-5b71aa4bd70bc26f8c3094e9969106ff47a99da024457354098f80e457af3fb53</citedby><cites>FETCH-LOGICAL-c448t-5b71aa4bd70bc26f8c3094e9969106ff47a99da024457354098f80e457af3fb53</cites><orcidid>0000-0001-8979-692X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002961017305317$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28622841$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>El HageChehade, Hiba</creatorcontrib><creatorcontrib>Wazir, Umar</creatorcontrib><creatorcontrib>Mokbel, Kinan</creatorcontrib><creatorcontrib>Kasem, Abdul</creatorcontrib><creatorcontrib>Mokbel, Kefah</creatorcontrib><title>Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature</title><title>The American journal of surgery</title><addtitle>Am J Surg</addtitle><description>Abstract Introduction Decision-making regarding adjuvant chemotherapy has been based on clinical and pathological features. However, such decisions are seldom consistent. Web-based predictive models have been developed using data from cancer registries to help determine the need for adjuvant therapy. More recently, with the recognition of the heterogenous nature of breast cancer, genomic assays have been developed to aid therapeutic decision-making. Methods We have carried out a comprehensive literature review regarding online prognostication tools and genomic assays to assess whether online tools could be used as valid alternatives to genomic profiling in decision-making regarding adjuvant therapy in early breast cancer. Results and conclusion s: Breast cancer has been recently recognized as a heterogenous disease based on variations in molecular characteristics. Online tools are valuable in guiding adjuvant treatment, especially in resource constrained countries. However, in the era of personalized therapy, molecular profiling appears to be superior in predicting clinical outcome and guiding therapy.</description><subject>Adjuvant</subject><subject>Adjuvant therapy</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Cost analysis</subject><subject>Decision making</subject><subject>Gene expression</subject><subject>Genetic testing</subject><subject>Genomes</subject><subject>Genomics</subject><subject>Internet</subject><subject>Literature reviews</subject><subject>Medical prognosis</subject><subject>Patients</subject><subject>Prediction models</subject><subject>Prognosis</subject><subject>Studies</subject><subject>Surgery</subject><subject>Systematic review</subject><issn>0002-9610</issn><issn>1879-1883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFksFu1DAQhi0EotuFRwBZ4sIlwU6cOLlQVYUCUiUOwNlynMni4MSL7Szsg_F-TLQLSL1wsWXrn280_z-EPOMs54zXr8ZcT2Ncwi4vGJc5q3LG6gdkwxvZZrxpyodkwxgrsrbm7IJcxjjik3NRPiYXRVMXRSP4hvx646mfnZ2B7oPfzT4ma3SyfqbJexdpgH2ACHOimh60sz3VLkGYUXMA1NAdzH6yZi0fLIJ21GLtV6DGzwl-JuoHqvtxOWhkpAA6TSsNf0EHd6QdfsVEjZ4NhCt6TeMxJpiQb7D5wcKPVbsCncXGOi0BnpBHg3YRnp7vLfly-_bzzfvs7uO7DzfXd5kRoklZ1Umuteh6yTpT1ENjStYKaNu65aweBiF12_aaFUJUsqwEa5uhYYAPPZRDV5Vb8vLExeG-LxCTmmw04JyewS9RceTIVhbo6pa8uCcd_YI2uVUlJRei5AxV1Ullgo8xwKD2wU46HBVnas1Vjeqcq1pzVaxSmCvWPT_Tl26C_m_VnyBRcHUSANqBpgUVjQW0tLcBTFK9t_9t8foewWCauAzuGxwh_ptGxUIx9WldrnW3uCxZVeL5G1jizw8</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>El HageChehade, Hiba</creator><creator>Wazir, Umar</creator><creator>Mokbel, Kinan</creator><creator>Kasem, Abdul</creator><creator>Mokbel, Kefah</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8979-692X</orcidid></search><sort><creationdate>20180101</creationdate><title>Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature</title><author>El HageChehade, Hiba ; Wazir, Umar ; Mokbel, Kinan ; Kasem, Abdul ; Mokbel, Kefah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-5b71aa4bd70bc26f8c3094e9969106ff47a99da024457354098f80e457af3fb53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adjuvant</topic><topic>Adjuvant therapy</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Cost analysis</topic><topic>Decision making</topic><topic>Gene expression</topic><topic>Genetic testing</topic><topic>Genomes</topic><topic>Genomics</topic><topic>Internet</topic><topic>Literature reviews</topic><topic>Medical prognosis</topic><topic>Patients</topic><topic>Prediction models</topic><topic>Prognosis</topic><topic>Studies</topic><topic>Surgery</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>El HageChehade, Hiba</creatorcontrib><creatorcontrib>Wazir, Umar</creatorcontrib><creatorcontrib>Mokbel, Kinan</creatorcontrib><creatorcontrib>Kasem, Abdul</creatorcontrib><creatorcontrib>Mokbel, Kefah</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>El HageChehade, Hiba</au><au>Wazir, Umar</au><au>Mokbel, Kinan</au><au>Kasem, Abdul</au><au>Mokbel, Kefah</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature</atitle><jtitle>The American journal of surgery</jtitle><addtitle>Am J Surg</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>215</volume><issue>1</issue><spage>171</spage><epage>178</epage><pages>171-178</pages><issn>0002-9610</issn><eissn>1879-1883</eissn><abstract>Abstract Introduction Decision-making regarding adjuvant chemotherapy has been based on clinical and pathological features. However, such decisions are seldom consistent. Web-based predictive models have been developed using data from cancer registries to help determine the need for adjuvant therapy. More recently, with the recognition of the heterogenous nature of breast cancer, genomic assays have been developed to aid therapeutic decision-making. Methods We have carried out a comprehensive literature review regarding online prognostication tools and genomic assays to assess whether online tools could be used as valid alternatives to genomic profiling in decision-making regarding adjuvant therapy in early breast cancer. Results and conclusion s: Breast cancer has been recently recognized as a heterogenous disease based on variations in molecular characteristics. Online tools are valuable in guiding adjuvant treatment, especially in resource constrained countries. However, in the era of personalized therapy, molecular profiling appears to be superior in predicting clinical outcome and guiding therapy.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28622841</pmid><doi>10.1016/j.amjsurg.2017.05.006</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-8979-692X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9610 |
| ispartof | The American journal of surgery, 2018-01, Vol.215 (1), p.171-178 |
| issn | 0002-9610 1879-1883 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1910797214 |
| source | Elsevier ScienceDirect Journals Complete |
| subjects | Adjuvant Adjuvant therapy Breast cancer Cancer Cancer therapies Chemotherapy Cost analysis Decision making Gene expression Genetic testing Genomes Genomics Internet Literature reviews Medical prognosis Patients Prediction models Prognosis Studies Surgery Systematic review |
| title | Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T22%3A12%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Do%20online%20prognostication%20tools%20represent%20a%20valid%20alternative%20to%20genomic%20profiling%20in%20the%20context%20of%20adjuvant%20treatment%20of%20early%20breast%20cancer?%20A%20systematic%20review%20of%20the%20literature&rft.jtitle=The%20American%20journal%20of%20surgery&rft.au=El%20HageChehade,%20Hiba&rft.date=2018-01-01&rft.volume=215&rft.issue=1&rft.spage=171&rft.epage=178&rft.pages=171-178&rft.issn=0002-9610&rft.eissn=1879-1883&rft_id=info:doi/10.1016/j.amjsurg.2017.05.006&rft_dat=%3Cproquest_cross%3E1977144310%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1977144310&rft_id=info:pmid/28622841&rft_els_id=S0002961017305317&rfr_iscdi=true |